204 related articles for article (PubMed ID: 31387567)
1. Molecular features of lung adenocarcinoma in young patients.
Chen Z; Teng X; Zhang J; Huang K; Shen Q; Cao H; Luo H; Yuan Y; Teng X
BMC Cancer; 2019 Aug; 19(1):777. PubMed ID: 31387567
[TBL] [Abstract][Full Text] [Related]
2. Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1.
Liu J; Liu Y
Pathol Res Pract; 2020 Feb; 216(2):152797. PubMed ID: 31926773
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the frequency of oncogenic driver mutations and correlation with clinicopathological characteristics in patients with lung adenocarcinoma from Northeastern Switzerland.
Grosse A; Grosse C; Rechsteiner M; Soltermann A
Diagn Pathol; 2019 Feb; 14(1):18. PubMed ID: 30744664
[TBL] [Abstract][Full Text] [Related]
4. Evolution of lung adenocarcinoma from preneoplasia to invasive adenocarcinoma.
Zhu J; Wang W; Xiong Y; Xu S; Chen J; Wen M; Zhao Y; Lei J; Jiang T
Cancer Med; 2023 Mar; 12(5):5545-5557. PubMed ID: 36325966
[TBL] [Abstract][Full Text] [Related]
5. Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma.
Tanaka K; Hida T; Oya Y; Yoshida T; Shimizu J; Mizuno T; Kuroda H; Sakakura N; Yoshimura K; Horio Y; Sakao Y; Yatabe Y
Cancer; 2017 May; 123(10):1731-1740. PubMed ID: 28177518
[TBL] [Abstract][Full Text] [Related]
6. Cell block-based RNA next generation sequencing for detection of gene fusions in lung adenocarcinoma: An institutional experience.
Wei S; Talarchek JN; Huang M; Gong Y; Du F; Ehya H; Flieder DB; Patchefsky AS; Wasik MA; Pei J
Cytopathology; 2023 Jan; 34(1):28-34. PubMed ID: 36062384
[TBL] [Abstract][Full Text] [Related]
7. Driver mutations of young lung adenocarcinoma patients with malignant pleural effusion.
Wu SG; Liu YN; Yu CJ; Yang JC; Shih JY
Genes Chromosomes Cancer; 2018 Oct; 57(10):513-521. PubMed ID: 30107055
[TBL] [Abstract][Full Text] [Related]
8. The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2).
Aisner DL; Sholl LM; Berry LD; Rossi MR; Chen H; Fujimoto J; Moreira AL; Ramalingam SS; Villaruz LC; Otterson GA; Haura E; Politi K; Glisson B; Cetnar J; Garon EB; Schiller J; Waqar SN; Sequist LV; Brahmer J; Shyr Y; Kugler K; Wistuba II; Johnson BE; Minna JD; Kris MG; Bunn PA; Kwiatkowski DJ;
Clin Cancer Res; 2018 Mar; 24(5):1038-1047. PubMed ID: 29217530
[No Abstract] [Full Text] [Related]
9. Oncogenic driver mutations in Swiss never smoker patients with lung adenocarcinoma and correlation with clinicopathologic characteristics and outcome.
Grosse C; Soltermann A; Rechsteiner M; Grosse A
PLoS One; 2019; 14(8):e0220691. PubMed ID: 31386689
[TBL] [Abstract][Full Text] [Related]
10. Assessment of mutational profile of Japanese lung adenocarcinoma patients by multitarget assays: a prospective, single-institute study.
Serizawa M; Koh Y; Kenmotsu H; Isaka M; Murakami H; Akamatsu H; Mori K; Abe M; Hayashi I; Taira T; Maniwa T; Takahashi T; Endo M; Nakajima T; Ohde Y; Yamamoto N
Cancer; 2014 May; 120(10):1471-81. PubMed ID: 24700479
[TBL] [Abstract][Full Text] [Related]
11. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
[TBL] [Abstract][Full Text] [Related]
12. Coexistent genetic alterations involving ALK, RET, ROS1 or MET in 15 cases of lung adenocarcinoma.
Tang Z; Zhang J; Lu X; Wang W; Chen H; Robinson MK; Cheng J; Tang G; Medeiros LJ
Mod Pathol; 2018 Feb; 31(2):307-312. PubMed ID: 28914263
[TBL] [Abstract][Full Text] [Related]
13. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
Byeon S; Lee B; Park WY; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532
[TBL] [Abstract][Full Text] [Related]
14. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.
Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C
Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879
[TBL] [Abstract][Full Text] [Related]
15. [Clinical features of 54 cases of lung adenocarcinomas with c-ROS oncogene 1 fusion].
Cao H; Zheng J; Zhao J; Guo XJ; Zhou JY; Ding W; Zhou JY
Zhonghua Jie He He Hu Xi Za Zhi; 2020 Feb; 43(2):120-125. PubMed ID: 32062881
[No Abstract] [Full Text] [Related]
16. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
Pan Y; Zhang Y; Li Y; Hu H; Wang L; Li H; Wang R; Ye T; Luo X; Zhang Y; Li B; Cai D; Shen L; Sun Y; Chen H
Lung Cancer; 2014 May; 84(2):121-6. PubMed ID: 24629636
[TBL] [Abstract][Full Text] [Related]
17. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
[TBL] [Abstract][Full Text] [Related]
18. Programmed death-ligand 1 expression and its associations with clinicopathological features, prognosis, and driver oncogene alterations in surgically resected lung adenocarcinoma.
Takamochi K; Hara K; Hayashi T; Kohsaka S; Takahashi F; Suehara Y; Suzuki K
Lung Cancer; 2021 Nov; 161():163-170. PubMed ID: 34600407
[TBL] [Abstract][Full Text] [Related]
19. [Relevance of molecular alterations in histopathologic subtyping of lung adenocarcinoma based on 2011 International Multidisciplinary Lung Adenocarcinoma Classification].
Liu B; Shi SS; Wang X; Xu Y; Zhang XH; Yu B; Lu ZF; Wang JD; Zhou XJ
Zhonghua Bing Li Xue Za Zhi; 2012 Aug; 41(8):505-10. PubMed ID: 23157740
[TBL] [Abstract][Full Text] [Related]
20. Detection of Novel NRG1, EGFR, and MET Fusions in Lung Adenocarcinomas in the Chinese Population.
Pan Y; Zhang Y; Ye T; Zhao Y; Gao Z; Yuan H; Zheng D; Zheng S; Li H; Li Y; Jin Y; Sun Y; Chen H
J Thorac Oncol; 2019 Nov; 14(11):2003-2008. PubMed ID: 31382039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]